Nonalcoholic Fatty Liver Disease and Acute Ischemic Stroke

To the Editor: In their recent commentary Takkouche and Norman seriously misrepresent the PRISMA guideline for reporting systematic reviews and meta-analyses. They state that PRISMA “demand s the prior registration of the protocol of any systematic review and meta-analysis, requiring that this protocol should be made accessible before any hands-on work is done.” No such demands are made in PRISMA. Item 5 of the checklist asks authors to “Indicate if a review protocol exists, if and where it can be accessed (such as Web address), and, if available, provide registration information including registration number.” The rationale for this request is: “registration may reduce unnecessary duplication of the same review question, particularly in jurisdictions with limited budgets; minimize study publication bias and selective reporting bias; and provide important information for those involved in updating systematic reviews.” That request anticipated the development of SR registration; indeed an international register is now being developed. Likewise, the PRISMA reporting guideline makes no statements as to the need for publication of a protocol prior to the initiation of the systematic review. It is possible that, as with the advent of clinical-trial registration, more avenues will appear whereby authors can publish protocols of such reviews. The authors also misrepresent the nature of registration, suggesting that this process would involve a judgement of originality and scientific merit of the planned research; we know of no such proposal. Takkouche and Norman also state “We also dispute the view that subgroup analyses and similar approaches should be used only if they were prespecified.” Again PRISMA makes no such demands on authors. Rather, the PRISMA explanatory paper says: “Having a protocol can help restrict the likelihood of biased post hoc decisions in review methods, such as selective outcome reporting.” In our explanatory article about PRISMA, we also recognized that “Authors may modify protocols during the research, and readers should not automatically consider such modifications inappropriate.” PRISMA seeks transparency and clarity: authors need to report how the systematic review was conducted to enable all readers to decide upon its merits. Lastly, we are not as confident as Takkouche and Norman about the effectiveness of peer review. A recent systematic review indicates that the peer review process is at best marginal and at worst ineffective. The scant research into the decision-making process of editors supports the need for clear and transparent reporting. David Moher Ottawa Methods Centre Ottawa Hospital Research Institute Ottawa, Ontario, Canada dmoher@ohri.ca

[1]  T. Jefferson,et al.  Editorial peer review for improving the quality of reports of biomedical studies. , 2007, The Cochrane database of systematic reviews.

[2]  G W Nicholson,et al.  ON TUMORS OF THE SALIVARY GLANDS. , 1918, Annals of surgery.

[3]  Naohito Yamaguchi,et al.  The INTERPHONE study: design, epidemiological methods, and description of the study population , 2007, European Journal of Epidemiology.

[4]  Thomas J. Stickrath,et al.  Ohio Department of Rehabilitation and Correction , 1997 .

[5]  Ross M. Kauffman,et al.  Measuring tobacco use in a prison population. , 2010, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[6]  James M Robins,et al.  The Identification of Synergism in the Sufficient-Component-Cause Framework , 2007, Epidemiology.

[7]  Tyler J VanderWeele,et al.  Statistical Applications in Genetics and Molecular Biology Epistatic Interactions , 2011 .

[8]  S. Sookoian,et al.  Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. , 2008, Journal of hepatology.

[9]  David Moher,et al.  An international registry of systematic-review protocols , 2011, The Lancet.

[10]  D. Williamson,et al.  Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults. The Adverse Childhood Experiences (ACE) Study. , 1998, American journal of preventive medicine.

[11]  Elisabeth Cardis,et al.  Cellular phone use and risk of benign and malignant parotid gland tumors--a nationwide case-control study. , 2008, American journal of epidemiology.

[12]  James M. Robins,et al.  Empirical and counterfactual conditions for sufficient cause interactions , 2008 .

[13]  M. Hernán,et al.  From counterfactuals to sufficient component causes and vice versa , 2007, European Journal of Epidemiology.

[14]  T. VanderWeele Attributable Fractions for Sufficient Cause Interactions , 2010, The international journal of biostatistics.

[15]  J. Vandenbroucke,et al.  Travel and Venous Thrombosis: An Exercise in Thinking About Bias , 2009, Annals of Internal Medicine.

[16]  K. Kalmbach,et al.  Ethical and legal standards for research in prisons. , 2003, Behavioral sciences & the law.

[17]  P. Boyle,et al.  Are cancers of the salivary gland increasing? Experience from Connecticut, USA. , 1997, International journal of epidemiology.

[18]  G. Targher,et al.  Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. , 2005, Diabetes.

[19]  S. Greenland,et al.  Invariants and noninvariants in the concept of interdependent effects. , 1988, Scandinavian journal of work, environment & health.

[20]  W. Flanders,et al.  On the relationship of sufficient component cause models with potential outcome (counterfactual) models , 2007, European Journal of Epidemiology.

[21]  J. Ioannidis,et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. , 2009, Journal of clinical epidemiology.

[22]  P. Trott,et al.  International Classification of Diseases for Oncology , 1977 .

[23]  B. Ljung,et al.  Environmental Factors and the Risk of Salivary Gland Cancer , 1997, Epidemiology.

[24]  J. Takeda,et al.  Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. , 2007, World journal of gastroenterology.